Amyloid beta protein levels in cerebrospinal fluid are elevated in early-onset Alzheimer's disease - PubMed (original) (raw)
Amyloid beta protein levels in cerebrospinal fluid are elevated in early-onset Alzheimer's disease
T Nakamura et al. Ann Neurol. 1994 Dec.
Abstract
The 4-kd amyloid beta protein (A beta) deposited as amyloid in Alzheimer's disease (AD) is produced and released by normal proteolytic processing of the amyloid beta protein precursor (beta APP) and is readily detected in cerebrospinal fluid (CSF). Here, we present the levels of A beta in CSF from a total of 95 subjects, including 38 patients with AD, 14 with early-onset AD and 24 with late-onset AD, 25 normal control subjects, and 32 patients with other neurological diseases. The level of A beta decreased with normal aging, and there was a significant elevation in the level of A beta in the CSF of early-onset AD patients (4.14 +/- 1.37 pmol/ml, p < 0.01). Neither Mini-Mental State nor Functional Assessment Staging were correlated with the amount of A beta in the CSF. The A beta/secreted form of beta APP ratio was elevated, but the level of alpha 1-antichymotrypsin in the CSF did not correlate with the level of CSF A beta in early-onset AD patients. Thus, the level of A beta in the CSF is elevated in early-onset AD patients and is suggested to be correlated with the pathology in the brain that characterizes AD.
Similar articles
- Soluble amyloid precursor proteins in the cerebrospinal fluid as novel potential biomarkers of Alzheimer's disease: a multicenter study.
Lewczuk P, Kamrowski-Kruck H, Peters O, Heuser I, Jessen F, Popp J, Bürger K, Hampel H, Frölich L, Wolf S, Prinz B, Jahn H, Luckhaus Ch, Perneczky R, Hüll M, Schröder J, Kessler H, Pantel J, Gertz HJ, Klafki HW, Kölsch H, Reulbach U, Esselmann H, Maler JM, Bibl M, Kornhuber J, Wiltfang J. Lewczuk P, et al. Mol Psychiatry. 2010 Feb;15(2):138-45. doi: 10.1038/mp.2008.84. Epub 2008 Jul 29. Mol Psychiatry. 2010. PMID: 18663368 - Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele.
Sunderland T, Mirza N, Putnam KT, Linker G, Bhupali D, Durham R, Soares H, Kimmel L, Friedman D, Bergeson J, Csako G, Levy JA, Bartko JJ, Cohen RM. Sunderland T, et al. Biol Psychiatry. 2004 Nov 1;56(9):670-6. doi: 10.1016/j.biopsych.2004.07.021. Biol Psychiatry. 2004. PMID: 15522251 - Longitudinal study of cerebrospinal fluid levels of tau, A beta1-40, and A beta1-42(43) in Alzheimer's disease: a study in Japan.
Kanai M, Matsubara E, Isoe K, Urakami K, Nakashima K, Arai H, Sasaki H, Abe K, Iwatsubo T, Kosaka T, Watanabe M, Tomidokoro Y, Shizuka M, Mizushima K, Nakamura T, Igeta Y, Ikeda Y, Amari M, Kawarabayashi T, Ishiguro K, Harigaya Y, Wakabayashi K, Okamoto K, Hirai S, Shoji M. Kanai M, et al. Ann Neurol. 1998 Jul;44(1):17-26. doi: 10.1002/ana.410440108. Ann Neurol. 1998. PMID: 9667589 - [Biochemical markers for Alzheimer disease].
Czarna JM, Waldemar G, Heegaard NH. Czarna JM, et al. Ugeskr Laeger. 2006 Mar 6;168(10):1010-4. Ugeskr Laeger. 2006. PMID: 16522291 Review. Danish. - Beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) as a biological candidate marker of Alzheimer's disease.
Hampel H, Shen Y. Hampel H, et al. Scand J Clin Lab Invest. 2009;69(1):8-12. doi: 10.1080/00365510701864610. Scand J Clin Lab Invest. 2009. PMID: 18609117 Review.
Cited by
- To Keto or Not to Keto? A Systematic Review of Randomized Controlled Trials Assessing the Effects of Ketogenic Therapy on Alzheimer Disease.
Grammatikopoulou MG, Goulis DG, Gkiouras K, Theodoridis X, Gkouskou KK, Evangeliou A, Dardiotis E, Bogdanos DP. Grammatikopoulou MG, et al. Adv Nutr. 2020 Nov 16;11(6):1583-1602. doi: 10.1093/advances/nmaa073. Adv Nutr. 2020. PMID: 32597927 Free PMC article. - What is the dominant Abeta species in human brain tissue? A review.
Gregory GC, Halliday GM. Gregory GC, et al. Neurotox Res. 2005;7(1-2):29-41. doi: 10.1007/BF03033774. Neurotox Res. 2005. PMID: 15639796 Review. - Effect of amyloid peptides on the increase in TrkA receptor expression induced by nicotine in vitro and in vivo.
Li XD, Arias E, Jonnala RR, Mruthinti S, Buccafusco JJ. Li XD, et al. J Mol Neurosci. 2005;27(3):325-36. doi: 10.1385/JMN:27:3:325. J Mol Neurosci. 2005. PMID: 16280603 - Amyloid precursor protein (APP) processing genes and cerebrospinal fluid APP cleavage product levels in Alzheimer's disease.
Bekris LM, Galloway NM, Millard S, Lockhart D, Li G, Galasko DR, Farlow MR, Clark CM, Quinn JF, Kaye JA, Schellenberg GD, Leverenz JB, Seubert P, Tsuang DW, Peskind ER, Yu CE. Bekris LM, et al. Neurobiol Aging. 2011 Mar;32(3):556.e13-23. doi: 10.1016/j.neurobiolaging.2010.10.020. Epub 2010 Dec 31. Neurobiol Aging. 2011. PMID: 21196064 Free PMC article. - Choroid Plexus in Alzheimer's Disease-The Current State of Knowledge.
Gião T, Teixeira T, Almeida MR, Cardoso I. Gião T, et al. Biomedicines. 2022 Jan 21;10(2):224. doi: 10.3390/biomedicines10020224. Biomedicines. 2022. PMID: 35203434 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical